McMMAF (Maleimidocaproyl monomethylauristatin F)

McMMAF (Maleimidocaproyl monomethylauristatin F) 是一种保护基团缀合的 MMAF。 MMAF 是一种有效的微管蛋白聚合抑制剂。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥825.00

660.00

- +
5mg

￥1462.00

1170.00

- +
10mg

￥2437.00

1950.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce52378
CAS: 863971-19-1
别名: Maleimidocaproyl monomethylauristatin F
分子式: C49H76N6O11
分子量: 925.16
纯度: >98%
溶解度: DMSO : ≥ 100 mg/mL (108.09 mM)
储存: Store at -20°C,unstable in solution, ready to use.
库存: 现货

Background

Mc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.Target:MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.

[1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69(6):2358-2364. [2]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.